Collaboration seeks to develop novel treatments for chronic liver diseases, including nonalcoholic steatohepatitis (NASH)
INGELHEIM, Germany & CAMBRIDGE, Mass. -- (BUSINESS WIRE) --
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment.
The option is the second target under the two companies’ research collaboration and license agreement. Under the terms of the agreement, Boehringer Ingelheim will be responsible for future clinical development and commercialization of the therapeutic target. Dicerna is eligible to receive development and commercial milestone payments, and royalties on worldwide net sales.
“It is extremely gratifying for Boehringer Ingelheim to exercise its option for a second therapeutic candidate from our productive research collaboration,” said Douglas M. Fambrough, President and Chief Executive Officer of Dicerna. “The option exercise underscores the potential of Dicerna’s GalXC technology platform in facilitating the discovery and development of novel RNAi therapies for nonalcoholic steatohepatitis and other chronic liver diseases. We look forward to continued progress and the potential advancement of clinical candidates from our partnership.”
Dicerna and Boehringer Ingelheim selected the target based on its ability to be drugged using Dicerna’s proprietary GalXC technology platform. The GalXC platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. The approach has the potential to treat diseases by silencing previously inaccessible drug targets.
“Boehringer Ingelheim is pleased with the progress of our initial collaboration with Dicerna and based on early findings and our strong relationship, we are expanding our research efforts,” said Clive R. Wood, Ph.D., Corporate Senior Vice President Discovery Research at Boehringer Ingelheim. “Today’s announcement exemplifies our commitment to discovering new therapies for NASH and other chronic liver diseases and advances our research efforts in this priority area.”
NASH is caused by the buildup of fat in the liver, potentially leading to liver fibrosis and cirrhosis. It has an especially high prevalence among obese and diabetic patients and is an area of high unmet medical need. NASH is expected to soon become the most common cause of advanced liver disorders, and it often necessitates liver transplantation.
Dicerna is building a portfolio of research and development programs to advance the treatment of diseases involving the liver, including chronic liver diseases, viral infectious diseases, cardiovascular diseases and rare diseases. The company aims to leverage its proprietary GalXC technology to develop innovative RNAi therapeutics to positively transform the lives of individuals living with these diseases.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Examples of forward-looking statements include, among others, statements Dicerna makes regarding: (i) the therapeutic and commercial potential of GalXC™; (ii) research and development plans related to GalXC; and (iii) the potential of our technology and drug candidates in our research and development pipeline. The process by which an early stage platform such as GalXC could potentially lead to an approved product is long and subject to highly significant risks, particularly with respect to a pre-clinical research collaboration. Applicable risks and uncertainties include those relating to Dicerna’s preclinical research and other risks identified under the heading "Risk Factors" included in Dicerna’s most recent Form 10-Q filing and in other future filings with the SEC. The forward-looking statements contained in this press release reflect Dicerna's current views with respect to future events, and Dicerna does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Carestream Health将其医疗保健IT业务
Spesolimab meets primary
Vifor Pharma and Angion
Aeternals:新型NFT和互动技术相结合
DCAS开始接受2024年非经销商委员会会员申请
Boehringer Ingelheim Launches
Rimini Street荣获多项客户销售与服务世界奖
聚豪情商务联盟携手天赐良田,玖夫牌富硒大米
IDEMIA和Resa Airport Data Syst
Kymeta 宣布其下一代天线、终端和全球移动连接
回顾激情燃烧的建设岁月 传承兰西拉艰苦奋斗
Mythical Games完成3700万美元C1轮融资
面对疫情和经济危机,亿康先达发布强劲的20
苏爱康医药宣布在日本推出Darvias®
Sabre选择DXC Technology来助力改变未
电池生产商Hithium将为储能系统开发商Perfect
全球投资者法律顾问ROSEN鼓励Athira Pharma
Mavenir的虚拟无线接入网(vRAN)连续第二年在
在大地上书写责任与担当——渭南师范学院孙樵
深圳三匹马出行科技与江铃集团新能源战略合作
森永乳业的益生菌长双歧杆菌BB536在其50周年庆
广成明股份参加番禺区先进制造业强区座谈会
村田首款面向Wi-Fi 6E/7的寄生元件耦合器实现商
Intelsat向史密森国家航空航天博物馆捐赠